Roach P J, Janicek M J, Kaplan W D
Department of Radiology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Clin Nucl Med. 1996 Sep;21(9):689-94. doi: 10.1097/00003072-199609000-00004.
Assessment of response to therapy in patients with lymphoma involving bone can be difficult. Of the scintigraphic techniques available, Tl-201 may be the most ideal radiopharmaceutical because it reflects tumor burden more accurately than either Tc-99m MDP or Ga-67 citrate. We compared serial Tl-201 and Ga-67 citrate scintigraphs (24 studies, 12 pairs) in assessing the response to therapy in three patients with non-Hodgkin's lymphoma involving bone. In two patients who demonstrated a complete remission, uptake of Tl-201 diminished more rapidly and returned to normal earlier than did Ga-67 citrate. Tl-201 did not show tumor recurrence in the one patient with lesions shown to be Tl-201 negative at baseline. Serial studies using Tl-201 may be superior to Ga-67 citrate in the evaluation of lymphoma involving bone provided that Tl-201 avidity is demonstrated on baseline studies.
评估累及骨骼的淋巴瘤患者对治疗的反应可能具有挑战性。在现有的闪烁显像技术中，铊-201（Tl-201）可能是最理想的放射性药物，因为它比锝-99m亚甲基二膦酸盐（Tc-99m MDP）或枸橼酸镓-67（Ga-67 citrate）更准确地反映肿瘤负荷。我们比较了连续的Tl-201和Ga-67 citrate闪烁显像（24项研究，12对），以评估3例累及骨骼的非霍奇金淋巴瘤患者对治疗的反应。在2例显示完全缓解的患者中，Tl-201的摄取比Ga-67 citrate更快减少并更早恢复正常。在1例基线时病变显示为Tl-201阴性的患者中，Tl-201未显示肿瘤复发。如果在基线研究中显示有Tl-201亲合性，那么使用Tl-201进行连续研究在评估累及骨骼的淋巴瘤方面可能优于Ga-67 citrate。
